Tag: DeSci

Crypto investor and founder Will Harborne will lead a new enterprise aimed at funding and supporting groundbreaking longevity technologies. From crypto to longevity The burgeoning field of longevity biotech is about to have a new player. Like many recent enterprises, such as Brian Armstrong’s NewLimit, this one is driven by someone coming from the crypto...

Thanks for joining us again for the latest edition of the Longevity and DeSci Recap. This month’s highlights include fantastic conferences, such as the Rejuvenation Startup Summit 2024 in Berlin, the Vitalia event in Roatan, and the large-scale Longevity Med Summit in Lisbon, along with many other industry insights. Upcoming conferences Join the Rejuvenation Startup...

Welcome back to the latest edition of the Longevity and DeSci Recap. Here, you’ll discover the latest interviews, insights, and research in the longevity tech sphere over the past month, and learn more about blockchain, DAOs, cryptocurrency, DeSci, and events. This October saw ExcepGEN, a genetic medicine start-up, raise $4 million in funding, taking their...

VitaDAO, a decentralized autonomous organization (DAO), has launched its first biotech, Matrix Biosciences. This is a real milestone for new models of funding for the scientific community. The launch is in collaboration with Vera Gorbunova from the University of Rochester's Aging Research Center and is well-known in the field for her work with naked mole...

Autumn is upon those of us in the Northern Hemisphere. A lot has happened, and as usual, we have been busy supporting human longevity research to end age-related diseases. The first talks from EARD2023 are available The Ending Age-Related Diseases 2023 (EARD2023) conference is over, and it was a huge success. This year's event focused...

The Ending Age-Related Diseases 2023 conference has ended, and it was a big success. Today, we are delighted to announce that the first of our conference videos is available: the opening talk from the event given by our President, Keith Comito. But before we get into that, we would like to thank those of you...